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Abstract
Background: A clinical trial was conducted in order to assess the efficacy of rifaximin, a broad-spectrum antibiotic
with negligible gastrointestinal absorption, in comparison with metronidazole, a commonly employed antimicrobial
drug, in dogs with chronic enteropathy. Twenty-four pet dogs were randomly enrolled into two different groups: MET
group (10 dogs) and RIF group (14 dogs). Dogs of MET group received metronidazole 15 mg/kg q12h for 21 days by
oral route, whereas dogs of RIF group, were given rifaximin 25 mg/kg q12h for 21 days by oral route. Clinical signs of
disease were evaluated the day before the beginning of drug administration (D0), and at the end of treatment (D21),
by means of Canine IBD Activity Index (CIBDAI). Blood levels of C-reactive protein (CRP) at D0 and D21 were also
measured, as another parameter of treatment efficacy. The primary outcome measure of efficacy was the complete
remission at D21, defined as a 75 % or greater decrease of CIBDAI; secondary outcome measures were the variation of
mean CIBDAI scores, of mean CRP serum levels, and any observed adverse effect from D0 to D21.
Results: Treatment with metronidazole or rifaximin greatly improved the clinical signs of disease in each group: in MET
group the complete remission was achieved in 8 of 10 dogs (80.0 %), and partial remission in 2 subjects (20.0 %). In RIF
group, 12 of 14 dogs showed complete remission (85.7 %), and the remaining 2 dogs were in partial remission (14.3 %).
There were also significant decreases of CIBDAI scores (P = 0.002 and P = 0.0002 for MET and RIF, respectively), and CRP
levels (P = 0.002 and P = 0.0001 for MET and RIF, respectively) compared to pre-treatment values in both groups. No
significant difference, however, was found when comparing MET and RIF groups. No relevant side-effect was reported
during the trial with either drugs.
Conclusions: The present study showed, for the first time, that oral rifaximin could represent an effective alternative to
metronidazole for the induction of clinical remission in dogs with chronic enteropathy.
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Background
Inflammatory bowel disease (IBD) is a generic name
which includes different chronic inflammatory disorders
affecting the gastrointestinal tract in human patients, the
most important of which are Crohn’s disease (CD) and
ulcerative colitis (UC). Dogs and cats are also susceptible
of developing chronic gastro-intestinal inflammation
which share several aspects with human IBD [1]. In
these species the most frequent histological forms of
chronic enteropathy are lymphocytic-plasmacytic enter-
itis (LPE) and eosinophilic gastroenteritis (EGE), and
while the clinical and histological features of IBD in
small animals are not always closely akin to those of CD
and UC, the pathogenesis of such diseases is thought to
be very similar. Indeed, it seems that an abnormal re-
sponse of the immune system due to a loss of tolerance
to different luminal antigens is the key pathogenetic
event of both human and animal IBD [2–4]. Though the
pathogenesis is still not fully understood, it is generally
accepted that IBD has a multifactorial etiology, and that
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genetic predisposition, together with environmental fac-
tors and a derangement of gut epithelial barrier, are all
contributing to the generation and/or perpetuation of
inflammation. Several studies suggest that a hyper-
reactivity of the immune system in the gut against nor-
mally well-tolerated antigens, like food components or
bacterial microbiota, ignites the inflammatory response
which is then responsible for gastrointestinal damage [2,
3]. Moreover, the inflammation is carried on and exacer-
bated by various problems such as resistance to apop-
tosis of lymphocytes and recurrent exposure to luminal
antigens due to an enhanced mucosal permeability [5–
7].
The treatment of CD or UC in human patients, as well as
in animals affected by IBD, is mainly based on the use of
anti-inflammatory and immunosuppressant drugs (cortico-
steroids, 5-aminosalicylates, azathioprine, cyclophospha-
mide) in order to normalize the up-regulated immune
response. Even though the drugs prescribed to dogs and
cats affected by IBD are often the same employed in human
patients, some forms of chronic enteritis in these species
respond to simple diet modification or to probiotics and
antimicrobial drugs [8, 9]. There are several evidences of
the importance of bacterial microbiota in the pathogenesis
or worsening of IBD [10–12] but, whereas antibiotics seem
to ameliorate experimental bowel inflammation [13–15],
the results obtained against CD or UC in clinical trials with
antibacterial agents are not very encouraging, except for
some positive effects obtained with metronidazole and cip-
rofloxacin [16, 17]. Metronidazole has proven to be effect-
ive also in small animal IBD [18], suggesting that bacteria
may play a role in chronic gastrointestinal inflammation of
dogs and cats, even if the real weight of antimicrobial
action compared with the immunomodulating activity
possessed by this drug has to be clarified yet.
Rifaximin (4-deoxy-4′-methylpyrido[1′,2′-1,2]imidazo-
[5,4-c]-rifamycin SV) is a semisynthetic rifamycin endowed
with a wide spectrum of antibacterial activity, and it is vir-
tually non-absorbable by oral route [19], thus granting high
efficacy and low incidence of side-effects [20]. Previous
studies showed that rifaximin was more effective than
other antibiotics in human patients with irritable bowel
syndrome (IBS), and induced remission of moderately
active CD in 2/3 of the subjects treated [21, 22]. Rifaximin
was also more active than metronidazole in human
patients with intestinal bacterial overgrowth [23]. Even
though an efficacy of this drug in human IBD and in ex-
perimental models of intestinal inflammation [15, 24, 25]
was demonstrated, as for metronidazole, the reasons
underlying this beneficial activity are still unclear.
The aim of the present study was to investigate the
therapeutic effects of oral rifaximin in dogs affected by
chronic entheropathy, compared with those of metro-
nidazole, an antimicrobial and antiprotozoal drug
commonly employed in the therapy of chronic intestinal
inflammation in small animals.
Methods
Animals
Thirty-six pet dogs, males and females, diagnosed with
chronic enteropathy both by clinical and histological evalu-
ation, were assessed for eligibility, and 25 of them, were
enrolled in the clinical trial (Fig. 1). The sample size was de-
termined on the basis of a previous similar study [26]. The
study was conducted between September 2014 and March
2016, at the Veterinary Hospital of the University of Parma,
apart from the histologic and biochemical analysis, which
were performed at the Idexx Laboratories. The animals
were included in the trial on the basis of the following
criteria: clinical signs of gastrointestinal disease lasting for
more than 3 weeks; lack of a relevant improvement after at
least 4 weeks of a commercial elimination diet (with the
recommendation to the owner to feed the dogs exclusively
with the prescribed diet), or after the treatment with
anthelmintic drugs, antibiotics (amoxicillin/clavulanic acid
or enrofloxacin), spasmolytic and antidiarrhoeal agents;
failure to detect other causes of disease after a thorough
diagnostic protocol. The diagnostic evaluation for all dogs
included at least CBC, serum biochemistry and urinalysis,
three daily consecutive faecal examinations for endopara-
sites (both by direct smear and by flotation technique),
faecal chymotrypsin and serum trypsin-like immunoreactiv-
ity, abdominal ultrasonography. Exclusion criteria were a
previous treatment with immunosuppressant drugs or the
presence of hypoalbuminemia (9 dogs); moreover, 2 dogs
with a suspected diagnosis of primary lymphangiectasis
were also not included in the study. The diagnosis of
chronic enteropathy was confirmed in all subjects by means
of endoscopy (Fujinon EG-250WR5), and subsequent
histologic evaluation of multiple biopsies.
Trial design
The dogs were randomly assigned to two different groups,
named MET (metronidazole) and RIF (rifaximin), with an
allocation ratio of 1:1. MET group was composed by 10
dogs, while the dogs assigned to RIF group were 15. One
of the dogs belonging to RIF group died before the
conclusion of the treatment period, and was therefore
excluded from the results. Each dog meeting the criteria
for enrolment in the trial was assigned to MET group if its
name was composed by an even number of letters, or to
RIF group if the name was instead made of an odd
number of letters.
Metronidazole was administered by oral route to the
dogs of MET group, at the dose of 15 mg/kg q12h for
21 days, whereas rifaximin, at the dose of 25 mg/kg
q12h for 21 days, was given by oral route to the dogs
enrolled in RIF group. Metronidazole was administered
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at a dose in the range commonly employed in the ther-
apy of IBD in dogs (10–25 mg/kg q12h) [18], whereas
the dosage used for rifaximin was chosen on the basis of
a previous work [15]. The dogs were examined for the
assessment of the severity score of the disease by a mem-
ber of our research group, blind to the treatment, the day
before the beginning of drug administration (D0), at day
15, and at day 21 (D21), at the end of metronidazole or
rifaximin administration period. All dogs received also
ranitidine (2 mg/kg q12h), and metoclopramide (0.3 mg/kg
q12h until day 15). A supplement of vitamin B12 (cyano-
cobalamin 250–1000 μg i.m. according to the weight) was
administered once a week to the dogs. In order to exclude
any influence of food on the evaluation of drug efficacy, all
dogs were fed with a home-made diet which consisted
exclusively of boiled chicken meat and rice.
Blood samples were collected from each dog at D0
(pre-treatment level) and at D21 (post-treatment level)
for the measurement of C-reactive protein (CRP), which
is an acute-phase protein produced by the liver in
response to inflammation, infection and tissue injury,
and whose decrease from pre-treatment serum level is
considered a suitable marker of the improvement of the
intestinal inflammatory status [27].
Drugs
A commercially available oral formulation of metronida-
zole, Flagyl® 250 mg tablets (Zambon Italia Srl, Milano,
Italy) was employed in the study. Rifaximin 250 mg
divisible tablets were kindly supplied by Ati Pets Srl,
Fatro Group SpA, Ozzano dell’Emilia, Bologna, Italy.
Clinical evaluation and measures of outcome
The severity of the disease was scored by means of
Canine IBD Activity Index (CIBDAI), which is a widely
accepted index of mucosal inflammation in canine IBD
[28]. Briefly, six salient clinical signs (attitude/activity,
appetite, vomiting, stool consistency, stool frequency,
weight loss) were assessed and scored 0 through 3,
according to the degree of alteration from normal in
each patient. The obtained scores were then summed in
order to obtained a cumulative CIBDAI score, indicating
the severity of the disease: clinically insignificant (0–3),
mild (4–5), moderate (6–8) or severe (9 or greater).
The primary outcome assumed as therapeutic
response to the treatment was clinical remission at D21,
according to a previous study [27]. Complete remission,
was defined as 75 % or greater decrease of CIBDAI score
with respect to pre-treatment (D0), while a reduction of
Fig. 1 Flow chart of trial enrolment and treatment protocol
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CIBDAI <75 % but >25 % was considered as a partial re-
mission. Secondary measures were the percent variation
of mean CIBDAI score from D0 to D21 in both groups,
and the modification of pre-treatment mean CRP serum
concentration at the end of treatment. Any adverse
effect observed during the trial was also considered as a
secondary outcome.
Histology
Tissue samples collected during endoscopy, after fixation
in 10 % buffered formalin, were processed according to
an automatised method (Tissue-Tek Xpress 120, Sakura
Finetek Europe B.V., Flemingweg, the Netherlands).
Serial paraffin sections (2 μm) were then prepared, and
stained with haematoxylin and eosin for morphological
examination. Histologic evaluation was performed by
two observers, blind to the treatment (Fig. 2).
C-reactive protein assay
CRP was measured by means of an immunoturbidi-
metric assay (Randox Canine CRP, Randox Laboratories
Ltd., U.K.). The reference range for CRP level in healthy
dogs measured with this assay is 0–10.7 mg/l.
Statistical analysis
The two different treatment groups were compared
about two outcome results (CIBDAI and CRP serum
level). Comparisons within the same group between pre-
and post-treatment values were made by means of non-
parametric Wilcoxon matched pairs signed rank tests;
whereas when the differences between MET group and
RIF group were analysed, cumulative distributions were
compared with Kolmogorov-Smirnov unpaired tests. All
statistical measures were performed using a commercial
software (GraphPad Prism, ver. 6.05, GraphPad Software
Inc., La Jolla, CA, U.S.A.).
Results
METgroup consisted of 10 dogs (3 cross-breeds, 2 German
Shepherds, 1 Rottweiler, 1 Boxer, 1 Golden Retriever, 1
Pinscher, 1 Épagneul Breton), whereas RIF group was
composed by 14 dogs (5 cross-breeds, 2 German
Shepherds, 1 Irish Setter, 1 Poodle, 1 Dachshund, 1 Boxer,
1 Dogo Argentino, 1 Maltese, 1 Bichon Frisè). Mean weight
at D0 was 21.65 ± 11.61 kg (range: 6–45) for dogs of MET
group, and 16.32 ± 8.47 kg (range: 5–28) for dogs belonging
to RIF group.
Histologic features of biopsies of all dogs showed an
inflammation with lymphocytic-plasmacytic infiltrate of
small intestinal mucosa, ranging from mild to severe,
often with alterations of the structure of villi (blunted or
fused). In particular, in MET group the number of dogs
with mild, moderate or severe inflammation, were 1, 6,
and 3, respectively. In the same group 5 dogs presented
blunted, and one dog fused villi. In RIF group, 4 dogs
showed mild, 7 moderate, and 4 severe inflammation. In
this group, 8 dogs showed blunted, and 2 fused villi.
At D21 in dogs of MET group the complete remission
was achieved in 8 of 10 animals (80.0 %), while 2
subjects were in partial remission (20.0 %). In RIF group,
12 of 14 dogs showed complete remission (85.7 %), and
the remaining 2 dogs were in partial remission (14.3 %)
(Fig. 3).
Mean CIBDAI scores at D0 were 7.70 ± 2.41 (range:
4–11) and 7.29 ± 2.61 (range: 3–11) for MET and RIF
group, respectively (P = 0.921). Treatment with metro-
nidazole or rifaximin, along with diet change, greatly im-
proved the clinical signs of disease in each group at D21,
as shown by the significant decrease of CIBDAI values,
compared to pre-treatment values (1.30 ± 1.83, P = 0.002,
and 0.92 ± 1.11, P = 0.0002, respectively) (Fig. 3). There
was, however, no significant difference between MET
Fig. 2 Histologic features of small intestine sections of dogs with LPE.
Panel a: Duodenal mucosa of a dog enrolled in MET group (CIBDAI
score 11 at D0) with severe lymphoplasmacytic inflammation. The
infiltrate of inflammatory cells is extending from the tip of the villi,
through the lamina propria, to the muscularis mucosae (haematoxylin
and eosin; 20×). Panel b: Duodenal mucosa of a dog enrolled in RIF
group (CIBDAI score 3 at D0), with moderate lymphoplasmacytic
inflammation. The villi are blunted, and the inflammatory cells are
scattered into the lamina propria (haematoxylin and eosin; 40×)
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and RIF groups in the percent decrease of CIBDAI
scores from pre-treatment level to D21 (85.84 vs
88.34 %, respectively, P = 0.999).
Mean CRP levels at D0 of dogs in MET group and RIF
group were 9.95 ± 1.71 mg/l and 10.46 ± 1.80 mg/l, respect-
ively (P = 0.974). After 3 weeks of both metronidazole and
rifaximin administration (D21), mean CRP serum levels
were significantly reduced (2.66 ± 1.42 mg/l, P = 0.002, and
2.23 ± 1.30 mg/l, P = 0.0001, respectively) (Fig. 4). The
decrease, expressed in percentage, of mean CRP concentra-
tion in MET group was 74.07 ± 12.45 %, whereas it was
79.75 ± 10.00 %, in dogs of RIF group, without achieving,
anyway, a significant difference (P = 0.446).
No significant adverse effect was observed during the
treatment period in both groups of dogs. Raw data of
CIBDAI scores, remission rates, dog weights, and CRP
serum levels are reported in Additional file 1.
Discussion
Treatment of canine chronic enteropathies is often
including antibacterial agents, based on the evidences of an
efficacy of antibiotic therapy in ameliorating clinical signs
of disease, and of a possible pathogenetic role of bacterial
antigens in the generation and perpetuation of inflamma-
tory status in the gastrointestinal mucosa [29, 30]. The
present study was aimed to compare the clinical efficacy of
rifaximin, a non-absorbable rifamycin, with respect to
metronidazole, an antibiotic commonly prescribed against
canine IBD, in dogs in which non-hypoproteinemic chronic
enteropathy was diagnosed. After the administration of
either antibiotic for 21 days, and diet modification, clinical
signs were greatly improved, as shown by the number of
Fig. 3 Effect of metronidazole and rifaximin administration on clinical remission rates (box) and CIBDAI scores (columns and symbols) of dogs in
both treatment groups. Columns in the graph represent mean ± SD, while symbols are individual CIBDAI scores of dogs in MET group and RIF
group at D0 and at D21. **P < 0.001 D21 vs D0; ***P < 0.0001 D21 vs D0
Fig. 4 Effect of metronidazole and rifaximin administration on CRP
serum levels of dogs in MET group and RIF group. Columns in the graph
represent mean ± SD. **P< 0.001 D21 vs D0; ***P< 0.0001 D21 vs D0
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dogs which achieved complete remission, and by the signifi-
cant fall of mean CIBDAI scores in both groups. There
was, however, no significant difference in efficacy between
metronidazole and rifaximin, which demonstrated to be
equally effective in this clinical trial.
The beneficial effect of metronidazole and rifaximin
against intestinal inflammation was confirmed by the sig-
nificant decrease of mean CRP serum concentration at D21
with respect to pre-treatment level in both groups, as the
correlation of this acute-phase protein with inflammatory
status in human and dog IBD has been observed in several
studies [27, 31]. However, since CRP is a non-specific
marker of inflammation, the interpretation of this result
should be prudently considered without further studies.
To date, little is known about the species of
microbiota which may play a role in the pathogenesis of
canine IBD. Whereas many studies have shown that an
alteration of gut microbiota takes place in dogs and cats
with chronic intestinal inflammation, and that this
dysbiosis is similar to those observed in human IBD or
in animal models of intestinal inflammation, the
composition of such abnormal bacteria population
seems to be variable, thus making the choice of a
selective antibiotic treatment a very difficult task [32]. In
the present study, rifaximin, a broad spectrum antibiotic,
was effective as metronidazole, whose activity is directed
only against anaerobes. This result seems to suggest that
anaerobic bacteria could be particularly important in the
pathogenesis of chronic diarrhoea in dogs; as a matter of
fact, a recent study [33] evidenced an increased number
of anaerobic species in the mucosa of dogs with chronic
enteropathies. By contrast, other studies conducted in
dogs with IBD, found either a reduction of anaerobic
bacteria [32] or no significant alterations compared to
healthy subjects [26]. Interestingly, it was observed that
rifaximin was able to enhance the growth of beneficial
bacteria such as Bifidobacteria or Faecalibacterium
praunsnitzii [34], and that a reduced population of
Faecalibacterium in particular, which seems to exert a
protective activity against intestinal inflammation [35], is
usually present in human patients and dogs with IBD
[26, 36, 37]. However, metronidazole, which resulted
effective as rifaximin in this clinical trial, is by contrast
known to decrease anaerobes such as Faecalibacterium,
and thus the protective role of some intestinal
microbiota against inflammation remains to be clarified.
Metronidazole, a nitroimidazole antibiotic, is widely
used for the treatment of IBD in dogs, both alone or in
combination with corticosteroids or immunosuppressant
drugs, even though its efficacy was investigated only in
few published studies [26, 27, 38, 39], and the
mechanisms by which it improves the clinical signs of
the disease are still to be fully understood. Likewise,
although abundant experimental evidence supports the
hypothesis that bacteria participate to the pathogenesis
of IBD in humans, and metronidazole was shown to be
effective in reducing disease severity in patients with CD
[16, 40], and equal or even superior to sulphasalazine in
another study [41], the real utility of this drug, or the
reasons underlying its beneficial activity, remain contro-
versial. It has been proposed that metronidazole could
be effective for its immuno-modulating properties rather
than for a simple antibacterial activity, since this drug is
able to suppress cell-mediated immunity [42, 43].
As for rifaximin, an open-label study on IBD patients
demonstrated an efficacy in decreasing disease activity
index [44], and a significant advantage of a 12-week
treatment with this antibiotic over placebo in inducing
clinical remission in mild-to-moderate CD [22]. Further-
more, rifaximin was proved to be effective in preventing
bacterial translocation into mesenteric lymph nodes, and
to ameliorate experimental colitis in mice [15].
Recently, a protective role by nuclear receptors like
pregnane X receptor (PXR), peroxisome proliferator-
activated receptor-γ and liver X receptor in IBD was
suggested by some studies [45–47]. In particular, PXR
ligand pregnenolone-16α-carbonitrile was able to amelior-
ate dextran sodium sulfate (DSS)-induced colitis in mice,
and such effect was related to a reduced expression of NF-
kB transcription factor [48]. Through NF-kB inhibition, a
repression of its target genes is obtained, leading to a
decrease in the production of pro-inflammatory mediators
like TNF-α, IL-1β and IL-6. Rifampicin and rifaximin are
known agonists at PXR [49], and the latter has been
recently investigated for its effects on experimental colitis
in the mouse, showing to protect against DSS-induced
damage by inhibiting NF-kB signaling inflammatory
cascade [24]. Since NF-kB activation has been observed in
dogs affected by LPE [50, 51], it is possible that rifaximin
efficacy could be due, at least in part, to its anti-
inflammatory activity. It is interesting to note that, tylosin,
a macrolide antibiotic employed in the treatment of
chronic diarrhoea in dogs [38], and which was effective
against experimental colitis in rats [52], is also endowed
with anti-inflammatory properties [53], thus strengthening
the hypothesis that antimicrobic agents which are effective
against chronic intestinal inflammations in dogs, might
aim at two distinct targets, the bacteria in the bowel
lumen, which trigger the immune response, and the
immune response itself.
In this clinical trial, no significant side-effect was ob-
served with either antibiotic treatment during the 21-days
administration. Several adverse effects are nevertheless re-
ported in literature following metronidazole administration,
and neurological toxicity is frequently reported [54, 55].
Even though data about rifaximin safety in dogs are thus
far lacking, this drug was devoid of adverse effects when
administered to rats up to 100 mg/kg for 6 months [56],
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and was shown to be safe and effective in children with
IBD [57], most probably because of its negligible intestinal
absorption through healthy or inflamed mucosa. Indeed,
rifaximin absorption was not modified by intestinal
inflammation in indomethacin-induced enteropathy in rats
[58]. However, a long-term evaluation of potential adverse
effects in dogs caused by rifaximin administration is
necessary in order to thoroughly assess the safety of this
antimicrobic drug. Negative effects due to antibiotic-
induced alteration of intestinal microbiota cannot be in fact
excluded, since, for instance, it was observed in a recent
study that antibiotic-responsive dogs with chronic enterop-
athies have worse outcome compared to those treated only
with diet modification [59].
A limitation of this clinical trial could be the relatively
small number of dogs evaluated, which might have not
allowed to unveil small differences of efficacy between
the two antibiotic treatments; moreover, a single dosage
for both rifaximin and metronidazole was employed,
thus possibly clouding the evidence of a dose-dependent
effect. Metronidazole, however, was administered at a
commonly employed dose, whose efficacy and relative
lack of major side-effects is generally accepted; as for
rifaximin instead, possible dose-related differences in
efficacy or adverse effects could not be ruled out.
Another limitation of the present study is represented by
the possible therapeutic role played by the home-made
diet, as it is a low-fat, highly digestible one, and some of
the dogs could have responded to diet modification. A
future clinical trial including a group of dogs treated
only with this kind of home-made diet, in comparison
with antibiotic administration, would be useful to better
enlighten the therapeutic effect of rifaximin. Further-
more, a contribution of antiemetic drugs to the improve-
ment of CIBDAI scores cannot be excluded. It would
also have been very important to include in the study
the effects of drug treatment in a longer period of time,
as chronic enteropathies are commonly relapsing after
therapy is discontinued; the evaluation at the conclusion
of the 3 weeks of treatment is, anyway, usually adequate
to assess the response to drugs, at least to evaluate the
ability to induce the remission of clinical signs [28]. Fur-
ther studies with different doses of rifaximin, and over a
longer period of time, will allow to better understand
the efficacy and safety profile of this new therapeutic
approach to chronic intestinal inflammation in dogs.
Moreover, supplementary studies about rifaximin activity
on different intestinal microbiota could be crucial to
broaden the knowledge on the clinical potential of this
antibiotic against chronic enteropathies in dogs.
Conclusions
This study suggests, for the first time, that rifaximin
may indeed represent an attractive alternative to
metronidazole for the therapy of chronic intestinal in-
flammations in dogs.
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